<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959919</url>
  </required_header>
  <id_info>
    <org_study_id>B1831081</org_study_id>
    <nct_id>NCT01959919</nct_id>
  </id_info>
  <brief_title>Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO</brief_title>
  <official_title>Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Hemophilia A Treated Both On Demand And On Prophylaxis With A New Factor VIII Delivery System FusENGO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate prospectively throughout a period of 3- 6  months and not to
      exceed 12 months (according to local therapeutic plans) patients experiences of treatment
      with Factor VIII  in the new device named FuseNGO, a new delivery system for Factor VIII
      compared to their previous  delivery system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Ease of use, Time taken to reconstitute, Ease of storage, Rapidity to infuse, Impact on daily life of the therapy both on physical and social/ affective  aspects, Perception about the therapy, Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Ease of use, Time taken to reconstitute, Ease of storage, Rapidity to infuse, Impact on daily life of the therapy both on physical and social/ affective  aspects, Perception about the therapy, Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm 1: Device</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Refacto FusENGO</intervention_name>
    <description>Dosage will be chosen by PI based on patient condition.</description>
    <arm_group_label>Arm 1: Device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 200 patients with Hemophilia A (all severity levels) will be enrolled in
        approximately 20 centers in Italy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who
             currently use FVIII treatment either prophylactically or on-demand using traditional
             factor VIII delivery mechanisms.

          -  Patients advised for any reason by their physician to switch to a new factor VIII
             delivery device,  namely FuseNGO, before receiving any details about this study or
             Patients who requested to be treated with a new factor VIII delivery device namely
             FuseNGO, before receiving any details about this study.

        Exclusion Criteria:

          -  Patients not previously recommended by their physician to switch to this new factor
             VIII delivery system or Patients who did not previously ask their physician to be
             switched to this new factor VIII delivery system.

          -  Patients for which it is anticipated that 10 infusions will not occur in the 12
             months following their inclusion in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Dipartimento Medicina Clinica e Sperimentale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1831081&amp;StudyName=Evaluation%20Of%20Acceptability%20And%20Satisfaction%20Of%20Hemophilia%20Patients%20Treated%20With%20FusENGO</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
